Editor: Antti Jekunen

The Evolution of Radionanotargeting towards Clinical Precision Oncology: A Festschrift in Honor of Kalevi Kairemo

eBook: US $89 Special Offer (PDF + Printed Copy): US $151
Printed Copy: US $107
Library License: US $356
ISBN: 978-1-68108-866-2 (Print)
ISBN: 978-1-68108-865-5 (Online)
Year of Publication: 2022
DOI: 10.2174/97816810886551220101


The Evolution of Radionanotargeting towards Clinical Precision Oncology is a remarkable book honoring Professor Kalevi Kairemo, who is known among academic and medical circles as a pioneer in novel radiolabeled therapeutics. This festschrift provides an overview of key advances in the field of radionanotargeting, and the directions for future development in patient care. Prof Kairemo’s research is based on multiomics, which involves multiple elements: genomics, transcriptomics, proteomics, metabolomics, microbiomics, epigenomics, exposome, imaging, and precision medicine, which is reflected by the unique collection of articles presented. The articles start from the angle of radionanotargeting and theragnostics leading to imaging and therapy, which includes sections for thyroid cancer, head and neck cancer, genitourinary cancers and neuroendocrine neoplasms. Theragnostics, nanoparticles and precision oncology have also been covered in their own segments, while also giving a glimpse of research in metabolic imaging, cardiovascular radionuclide imaging, and bone therapies. The sequence of chapters demonstrates how, through Professor Kairemo’s efforts, radionanotargeting has evolved to a practice changing therapeutic approach in the clinic, particularly in oncology. Finally, Professor Kairemo’s own memoir, “Seven decades in health care” and memoirs from colleagues including a personal introduction to him with a photographic cavalcade reveals the world of a multitasking person with a multidisciplinary approach to science, that ushered his development of significant expertise across the fields of chemistry, biology, engineering, physics and clinical medicine. This book is excellent for medical historians, trainees and specialists in clinical and radiological oncology in expanding their understanding of the role of radionuclide imaging over the years, making it an ideal tribute that belongs in the library of anyone involved in the field.


- Pp. i-iii (3)
Andrew M. Scott, Homer A. Macapinlac, Steven M. Larson
Download Free


- Pp. iv-v (2)
Antti Jekunen
Download Free

List of Contributors

- Pp. vi-x (5)

Download Free

Molecular Imaging in the Development of Antibody-Drug Conjugates

- Pp. 1-14 (14)
Clare Senko, Sze-Ting Lee*, Hui K. Gan, Umbreen Hafeez, Sagun Parakh, Andrew M. Scott
View Abstract

Preclinical Applications with Phage Displayderived Peptides

- Pp. 15-18 (4)
Erkki Koivunen*
View Abstract

Perspectives in 11C and 18F Radiochemistry

- Pp. 19-31 (13)
Hugo Helbert, Gert Luurtsema, Rudi A.J.O. Dierckx*, Wiktor Szymanski, Ben L. Feringa, Philip H. Elsinga
View Abstract

Introduction to Radionanotargeting in the 1990's: Dosimetry and Optimization of Antisense Oligonucleotide Radiotherapy in Vivo

- Pp. 32-39 (8)
Antti Jekunen*, Mikko Tenhunen, Kalevi Kairemo
View Abstract

Role of SPECT/CT Imaging with Gamma-emitted Radionuclides in Personalized Treatment of Cancer Patients

- Pp. 40-78 (39)
Sonya Sergieva*
View Abstract

Radionanotargeting and Precision Radiotherapy Planning in Patients with Breast Cancer

- Pp. 79-90 (12)
Pavel Krzhivitskiy*, Sergey Novikov, Sergey Kanaev, Petr Krivorotko
View Abstract

The Diagnostic Potential of Radiolabelled Neurotensin in PET Imaging of Patients with Pancreatic Cancer: Results from In Vivo, Animal And Human Studies

- Pp. 91-100 (10)
Marina Hodolic*
View Abstract

Dr. Saul Hertz (1905–1950) Discovers the Medical Uses of Radioactive Iodine: The First Targeted Cancer Therapy

- Pp. 101-110 (10)
Barbara Hertz*
View Abstract

Dosimetric Approach to Radioactive Iodine Therapy of Differentiated Thyroid Cancer

- Pp. 111-118 (8)
Hee-Seung Henry Bom*
View Abstract

Extent of Surgery and Following Treatment Depending on The Risk Evaluation of Thyroid Cancer

- Pp. 119-134 (16)
Ilya V. Sleptsov*
View Abstract

The Rise of Biopharmaceuticals and Immuno-PET: Where Pharmacy and Radiopharmacy Meet

- Pp. 135-145 (11)
Guus A.M.S. van Dongen*
View Abstract

In the Wake of European Winds and Head and Neck Radioisotope Imaging

- Pp. 146-151 (6)
Erkki Hopsu*
View Abstract

Radionuclide Management of Prostate Cancer: Molecular Targeting of Tumour; Strategic Targeting of Patients

- Pp. 152-163 (12)
J. Harvey Turner*
View Abstract

Ga-PSMA PET/CT for Patients with Prostate Cancer with PSA Relapse

- Pp. 164-178 (15)
Finn Edler von Eyben*
View Abstract

Imaging Bladder Cancer

- Pp. 179-208 (30)
Manisha Kumari, Sushil Tripathi, Mathew Thakur*
View Abstract

Radiomolecular Therapy of Neuroendocrine Character, Positive for sst2 Receptor Hepatocellular Malignancies

- Pp. 209-220 (12)
G.S. Limouris*
View Abstract

Theranostics in Japan

- Pp. 221-231 (11)
Seigo Kinuya*
View Abstract

Theragnostics in Austria

- Pp. 232-245 (14)
Irene Virgolini*
View Abstract

Precision Oncology Through Radiating Bullets: What All We Have Conquered and What All We Have To

- Pp. 246-254 (9)
Partha S Choudhury*, Manoj Gupta
View Abstract

Current Status of PSMA Targeted Alpha Therapy in Prostate Cancer Patients

- Pp. 255-264 (10)
Thabo Lengana*, Mike Sathekge
View Abstract

Nanotheranostics: A Dream Coming True

- Pp. 265-271 (7)
Oula Penate Medina*, Tuula Penate Medina
View Abstract

“Fit for Purpose” 64Cu Labeled Liposome Formulations Specialized for Enriched Targeting to 1) Bone Marrow Spleen; 2) lymph Nodes; or 3) Tumor

- Pp. 272-276 (5)
Sang-Gyu Lee*, Kishore Pillarsetty, Steven M. Larson
View Abstract

Theranostics at the Crossroads of Precision Health and Precision Medicine

- Pp. 277-281 (5)
Hossein Jadvar*
View Abstract

Oncolytic Immunotherapy: From Spontaneous Regression to Development of Armed Gene Modified Viruses

- Pp. 282-294 (13)
Akseli Hemminki*, Joao M. Santos
View Abstract

Boron Neutron Capture Therapy and Targeted Alpha Therapy for Intractable Cancers Combined with Positron Emission Tomography/Computed Tomography

- Pp. 295-308 (14)
Jun Hatazawa*
View Abstract

Targeting Imaging Brain Lesions with PET/CT: F18-CH and F-18-FLT

- Pp. 309-316 (8)
Alexandra Nikaki*
View Abstract

FDG Uptake by Brown Adipose Tissue in Paediatric and Adolescent Hodgkin Lymphoma, Visualised on PET/CT Performed at Diagnosis

- Pp. 319-328 (10)
Linda Jorgov*, Anne-Ségolène Cottereau, Sona Balogova, Françoise Montravers, Jean-Noël Talbot
View Abstract

[99mTc]Tc – MIBI as Oncologic Radiotracer

- Pp. 329-340 (12)
Raluca Mititelu*
View Abstract

The Actual Role of Nuclear Molecular Imaging in the Follow-up of Chemotherapy-Induced Cardiac Dysfunction

- Pp. 341-358 (18)
Taner Erselcan
View Abstract

Quantitation of Myocardial Perfusion using 15OWater PET: From a Research Tool to Clinical Routine

- Pp. 359-367 (9)
Juhani Knuuti*
View Abstract

Bone Targeted Radionuclide Therapy in Russia From Beta- to Alpha- Emitters

- Pp. 368-383 (16)
N.G. Seleva, V.V. Krylov*, T.Yu. Kochetova
View Abstract

Role of Beta-Emitter Sm-153 in Combined and Complex Therapy of Skeletal Metastases

- Pp. 384-394 (11)
Nigora Rasulova*
View Abstract

Molecular Radiobiology and Radionuclides Therapy Concepts

- Pp. 395-408 (14)
Aisyah Elliyanti*
View Abstract

War and Peace Inside - imaging Immune Attack in Blood Vessels

- Pp. 409-417 (9)
Seppo Meri*
View Abstract

Observations on Russia’s COVID-19 Politics

- Pp. 418-423 (6)
Markku Kangaspuro*
View Abstract

Radiomics Analysis of 177Lu-PSMA I&T Radioligand Therapy Dosimetry in a Castration Resistant Metastatic Prostate Cancer Patient

- Pp. 424-429 (6)
Eve Kelk*
View Abstract

Dancing in the Rain. Cancer as a Personal Experience

- Pp. 430-439 (10)
J.P. Roos*
View Abstract

The Flat Earth: Working with Patients and Patient Advocates in our Connected World

- Pp. 440-443 (4)
Josh Mailman*
View Abstract


- Pp. 444-489 (46)

Download Free

Subject Index

- Pp. 490-501 (12)

Download Free


.Colorectal Cancer Diagnosis and Therapeutic Updates.
.Nanotherapeutics for the Treatment of Hepatocellular Carcinoma.
.Topics in Anti-Cancer Research.
.Frontiers in Clinical Drug Research - Anti-Cancer Agents.